Koers Vital Therapies Inc Nasdaq
Aandelen
US92847R1041
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 116 mln. 107 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -99 mln. -91,24 mln. | Nettowinst (verlies) 2025 * | -100 mln. -92,17 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | 33,12 mln. 30,53 mln. | Nettoschuld 2025 * | 55,55 mln. 51,2 mln. | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-1,3
x | K/w-verhouding 2025 * |
-1,47
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 92,28% |
Recentste transcriptie over Vital Therapies Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Daniel Vitt
CEO | Chief Executive Officer | 55 | 01-01-17 |
Glenn Whaley
DFI | Director of Finance/CFO | 56 | 01-12-19 |
Hella Kohlhof
CTO | Chief Tech/Sci/R&D Officer | 51 | 01-01-17 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Barclay Phillips
BRD | Director/Board Member | 61 | 19-11-19 |
Tamar Howson
BRD | Director/Board Member | 75 | 11-10-19 |
Jörg Neermann
BRD | Director/Board Member | 57 | 01-04-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+7,61% | 115 mld. | |
+12,72% | 107 mld. | |
-13,44% | 22,31 mld. | |
-3,99% | 21,6 mld. | |
-6,38% | 18,23 mld. | |
-39,93% | 17,62 mld. | |
+6,84% | 14,26 mld. | |
+32,81% | 12,37 mld. | |
-27,83% | 8,28 mld. |